標題: Titlebook: Balloon pulmonary angioplasty in patients with CTEPH; Francesco Saia,Nazzareno Galiè,Hiromi Matsubara Book 2022 Springer Nature Switzerlan [打印本頁] 作者: BULK 時間: 2025-3-21 17:26
書目名稱Balloon pulmonary angioplasty in patients with CTEPH影響因子(影響力)
書目名稱Balloon pulmonary angioplasty in patients with CTEPH影響因子(影響力)學(xué)科排名
書目名稱Balloon pulmonary angioplasty in patients with CTEPH網(wǎng)絡(luò)公開度
書目名稱Balloon pulmonary angioplasty in patients with CTEPH網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Balloon pulmonary angioplasty in patients with CTEPH被引頻次
書目名稱Balloon pulmonary angioplasty in patients with CTEPH被引頻次學(xué)科排名
書目名稱Balloon pulmonary angioplasty in patients with CTEPH年度引用
書目名稱Balloon pulmonary angioplasty in patients with CTEPH年度引用學(xué)科排名
書目名稱Balloon pulmonary angioplasty in patients with CTEPH讀者反饋
書目名稱Balloon pulmonary angioplasty in patients with CTEPH讀者反饋學(xué)科排名
作者: 夜晚 時間: 2025-3-21 23:48
http://image.papertrans.cn/b/image/180504.jpg作者: 愛管閑事 時間: 2025-3-22 03:19 作者: 吸引人的花招 時間: 2025-3-22 04:40 作者: Incorporate 時間: 2025-3-22 11:26 作者: Liability 時間: 2025-3-22 15:50
Untergrundvorbereitung mit Fr?swerkzeugend drug therapy. Anticoagulation has been traditionally with oral vitamin K antagonists (VKA), but direct oral anticoagulants (DOACs) represent an attractive alternative, although some controversy exists. The rationale in support of PH-targeted medical therapy in CTEPH includes histopathological obse作者: opalescence 時間: 2025-3-22 19:40
Handbuch der Oberfl?chenbearbeitung Betonons for coronary or peripheral arteries. However, because of the unique features of pulmonary vasculature and disease, some differences between BPA and other interventions exist. Pulmonary vessel walls are fragile and vascular injury during procedures can easily cause life-threatening complications.作者: Ardent 時間: 2025-3-22 23:06 作者: 錯 時間: 2025-3-23 04:07 作者: dictator 時間: 2025-3-23 07:24 作者: Valves 時間: 2025-3-23 11:44 作者: BOOR 時間: 2025-3-23 17:21
Anforderungen an Schutzschichten,ertension (CTEPH) who are not candidates for pulmonary endarterectomy. With increasing physicians’ expertise, improvement of clinical results, and worldwide diffusion of the technique, definition of treatment goals has become crucial. The efficacy of BPA could be assessed from the patient’s perspect作者: cartilage 時間: 2025-3-23 19:03 作者: 暫時別動 時間: 2025-3-24 00:30 作者: 大罵 時間: 2025-3-24 03:38
Mag. Monique Weissenberger-Leducal scenarios, from asymptomatic patients with complete functional recovery to chronic thromboembolic pulmonary hypertension. In the middle lies the concept of chronic thromboembolic pulmonary?disease that identifies a subgroup of patients with persistent thrombotic lesions, symptoms on exertion, and作者: Anhydrous 時間: 2025-3-24 07:32
https://doi.org/10.1007/978-3-030-95997-5Pulmonary arterial hypertension; Pulmonary endarterectomy; Thoracic surgery; Pulmonary embolism; Chronic作者: Glossy 時間: 2025-3-24 13:58
978-3-030-95999-9Springer Nature Switzerland AG 2022作者: 維持 時間: 2025-3-24 17:25
Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension,thelialised pulmonary thrombi, leading to chronic obstruction and progressive arteriopathy of the pulmonary arterial tree. This causes a rise in pulmonary vascular resistance and pulmonary hypertension and culminates in right-heart failure. This chapter summarises advances in CTEPH epidemiology and 作者: 持久 時間: 2025-3-24 22:58
Diagnosis of Chronic Thromboembolic Pulmonary Hypertension,gnosis is pivotal for successful treatment. Current guidelines recommend that all patients with suspected CTEPH be referred to an expert centre for an accurate differential diagnosis and evaluation of the best treatment strategy to be performed by a multidisciplinary team. Ventilation/perfusion (V/Q作者: Spongy-Bone 時間: 2025-3-24 23:18 作者: Engaging 時間: 2025-3-25 05:30
Medical Treatment of Chronic Thromboembolic Pulmonary Hypertension,d drug therapy. Anticoagulation has been traditionally with oral vitamin K antagonists (VKA), but direct oral anticoagulants (DOACs) represent an attractive alternative, although some controversy exists. The rationale in support of PH-targeted medical therapy in CTEPH includes histopathological obse作者: 拍下盜公款 時間: 2025-3-25 10:24
Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: Modern Technique,ons for coronary or peripheral arteries. However, because of the unique features of pulmonary vasculature and disease, some differences between BPA and other interventions exist. Pulmonary vessel walls are fragile and vascular injury during procedures can easily cause life-threatening complications.作者: Alopecia-Areata 時間: 2025-3-25 13:27
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Clinical Outcomes,thrombus plane in the proximal pulmonary artery and removal of a dissectate that represents the inside of the pulmonary arterial tree. However, a considerable proportion of patients are not eligible for surgery due to distal lesions or due to comorbidities resulting in an unfavorable risk/benefit ra作者: 鐵砧 時間: 2025-3-25 16:24 作者: palpitate 時間: 2025-3-25 21:17
Advanced Noninvasive Imaging to Guide Balloon Pulmonary Angioplasty,y hypertension (CTEPH) who are not candidates for pulmonary endarterectomy. However, we need to further improve the outcome, efficiency, and safety of BPA. In this context, it is important to sufficiently use noninvasive imaging such as computed tomography and cardiovascular magnetic resonance to gu作者: 易發(fā)怒 時間: 2025-3-26 02:34
Balloon Pulmonary Angioplasty in Proximal Lesions,patients cannot be candidates for PEA because of age or comorbidities, even though the lesions are surgically accessible and suitable for PEA. It is unclear whether balloon pulmonary angioplasty (BPA) can become an alternative treatment for such patients. In this chapter, we focus on the effectivene作者: 允許 時間: 2025-3-26 06:24 作者: 不安 時間: 2025-3-26 12:11 作者: inventory 時間: 2025-3-26 15:01
Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: What Does the Futurreports were hampered by high adverse event rates, subsequent refinement and characterization of safe procedural technique have led to a significant decline in the all-comer adverse event rate, proving BPA to be a safe and effective therapy in selected patients with chronic thromboembolic pulmonary 作者: motivate 時間: 2025-3-26 19:00 作者: Sigmoidoscopy 時間: 2025-3-26 21:15
and its potential..Exploring the clinical indications and technical aspects of BPA, this book offers a valuable reference guide for all those who would like to introduce or improve a BPA program, and for all those whose work involves treating this complex patient population..978-3-030-95999-9978-3-030-95997-5作者: MANIA 時間: 2025-3-27 04:28
Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension,m and disordered thrombus resolution in disease initiation and revisit updated molecular mechanisms relevant to small-vessel remodelling in CTEPH including recent developments around proposed genetic contributors. Finally we review the varying impact on RV function in response to chronic thrombotic 作者: 漂浮 時間: 2025-3-27 07:08 作者: 改變 時間: 2025-3-27 11:36
Pulmonary Thromboendarterectomy: The Only Cure for Chronic Thromboembolic Pulmonary Hypertension,er, I will discuss the evidence for pulmonary endarterectomy (PTE) as a cure for CTEPH, and where this surgical treatment differs from balloon pulmonary angioplasty (BPA). As with many major surgical procedures, this evidence is derived from case series and registries, as there has never been a rand作者: Incorporate 時間: 2025-3-27 17:01
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Clinical Outcomes, (RCT) testing the relative efficacy and safety of BPA against PEA are missing at this time, and a single RCT that tested the efficacy and safety of BPA against medical therapy with riociguat suggested greater efficacy of BPA but at the price of higher complication rates..This chapter summarizes cur作者: Confidential 時間: 2025-3-27 19:28
Metrics for Success of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertensieral lesions in different lung territories. Hence, definition of metrics for success at a lesion level is a necessary step to guide the BPA procedures. To date, the best targets for BPA at the lesion level are normalization of pulmonary flow grade (PFG?=?3) and abrogation of pressure gradient throug作者: 顯赫的人 時間: 2025-3-28 01:41
Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: What Does the Futurh other treatment modalities for CTEPH. The results of two randomized controlled trials comparing BPA with medical therapy alone will help define the role of BPA within the algorithm for the treatment of CTEPH..As a field, BPA requires standardization in reporting of outcomes and complications to en作者: cluster 時間: 2025-3-28 02:58
Anforderungen an die Betonoberfl?chem and disordered thrombus resolution in disease initiation and revisit updated molecular mechanisms relevant to small-vessel remodelling in CTEPH including recent developments around proposed genetic contributors. Finally we review the varying impact on RV function in response to chronic thrombotic 作者: Magisterial 時間: 2025-3-28 10:20
https://doi.org/10.1007/3-7643-7373-3the complexity of pathophysiologic changes occurring in CTEPH, right-heart catheterisation (RHC) is still mandatory to confirm the diagnosis of pulmonary arterial hypertension (PAH) and to assess the degree of haemodynamic impairment. This chapter describes the diagnostic workup that is commonly use作者: 血友病 時間: 2025-3-28 13:15
https://doi.org/10.1007/3-7643-7373-3er, I will discuss the evidence for pulmonary endarterectomy (PTE) as a cure for CTEPH, and where this surgical treatment differs from balloon pulmonary angioplasty (BPA). As with many major surgical procedures, this evidence is derived from case series and registries, as there has never been a rand作者: apiary 時間: 2025-3-28 18:36
Definition der Vorbereitungsziele (RCT) testing the relative efficacy and safety of BPA against PEA are missing at this time, and a single RCT that tested the efficacy and safety of BPA against medical therapy with riociguat suggested greater efficacy of BPA but at the price of higher complication rates..This chapter summarizes cur作者: Ventilator 時間: 2025-3-28 22:06 作者: 發(fā)怨言 時間: 2025-3-29 00:49
Mag. Monique Weissenberger-Leduch other treatment modalities for CTEPH. The results of two randomized controlled trials comparing BPA with medical therapy alone will help define the role of BPA within the algorithm for the treatment of CTEPH..As a field, BPA requires standardization in reporting of outcomes and complications to en作者: Muffle 時間: 2025-3-29 04:35
Balloon pulmonary angioplasty in patients with CTEPH作者: synovium 時間: 2025-3-29 10:52 作者: 蔑視 時間: 2025-3-29 12:45
Untergrundvorbereitung mit Fr?swerkzeugen with PH-targeted medical therapy from randomized controlled trials (RCT)..In this chapter, the rationale and accumulating data in support of medical therapy in CTEPH will be reviewed. Unanswered questions in need of investigation and careful consideration include the role of these medical therapies.作者: 刺耳 時間: 2025-3-29 17:46 作者: acrimony 時間: 2025-3-29 20:04
Medical Treatment of Chronic Thromboembolic Pulmonary Hypertension, with PH-targeted medical therapy from randomized controlled trials (RCT)..In this chapter, the rationale and accumulating data in support of medical therapy in CTEPH will be reviewed. Unanswered questions in need of investigation and careful consideration include the role of these medical therapies.作者: Antarctic 時間: 2025-3-30 02:47 作者: hurricane 時間: 2025-3-30 05:22
Book 2022cations and technical aspects of BPA, this book offers a valuable reference guide for all those who would like to introduce or improve a BPA program, and for all those whose work involves treating this complex patient population..作者: crease 時間: 2025-3-30 10:04
on pulmonary angioplasty in patients with CTEPHThe only curative treatment currently available for chronic thromboembolic pulmonary hypertension (CTEPH) is surgical pulmonary endoarterectomy (PEA). However, several patients may have high risk factors for surgery, or a peripheral disease not amenable
